We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01180907
First Posted: August 12, 2010
Last Update Posted: July 31, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
August 11, 2010
August 12, 2010
July 31, 2012
November 2007
November 2011   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01180907 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample
patients with cancer, autoimmune diseases and healthy subjects
  • Cancer
  • Inflammation
Not Provided
  • patients with cancer
  • patients with autoimmune diseases
  • healthy subjects
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
Not Provided
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with cancer or autoimmune diseases or healthy subjects
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01180907
07-07-071
DE-PS02-08ER-08-01 ( Other Grant/Funding Number: Department of Energy )
CIRMNo. RT1-01126-1 ( Other Grant/Funding Number: California Institute for Regenerative Medicine )
10-000269 ( Other Identifier: UCLA Medical IRB#2 )
No
Not Provided
Not Provided
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Not Provided
Principal Investigator: Christiaan Schiepers, M.D. Ph.D University of California, Los Angeles
Jonsson Comprehensive Cancer Center
July 2012